[The Berlin Model. A multicenter study of prednicarbate in various vehicles].
We report on the results of an openly conducted multicenter study concerning efficacy and tolerance of a new prednisolone derivative free from halogenic groups (prednicarbate 0.25%, Dermatop) prepared as a) emulsifiable greasy ointment without water, b) w/o emulsion (ointment), and c) o/w emulsion (cream). These preparations were therapeutically applied in eczema (allergic, seborrheic, microbic), psoriasis, and atopic dermatitis. The study was carried out in close team work between a clinic and 37 practicing dermatologists and included 383 patients. After 3 weeks therapy, 4% of the patients did not reveal any satisfying results; 16% showed medium outcome with some persisting symptoms; in 80% of the patients, we observed good to very good therapeutic results.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001604:Berlin; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003872:Dermatitis / Q000188:drug therapy*; D003876:Dermatitis, Atopic / Q000188:drug therapy; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D004485:Eczema / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014677:Pharmaceutical Vehicles; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D014677:Pharmaceutical Vehicles; D011239:Prednisolone; C035287:prednicarbate
Das "Berliner Modell" Multicenterstudie mit Prednicarbat in verschiedenen Vehikeln.